ICG Enterprise Trust announces realisation of Datasite
22 July 2025
ICG Enterprise Trust announces realisation of Datasite, its fourth largest portfolio company
ICG Enterprise Trust plc (“ICGT”) is pleased to announce that it has fully realised its co-investment1 in Datasite, a provider of software focused on virtual data rooms. At 31 January 2025, Datasite was ICGT’s fourth largest company exposure, accounting for 1.9% of the Portfolio value. The co-investment portion accounted for 1.6% of the Portfolio value.
As a result of the sale ICGT has received cash proceeds of $30 million (£22 million), representing a 3% premium to the valuation at Q1 FY26.
ICGT made an $18 million co-investment (£14 million) in Datasite alongside ICG Strategic Equity V and CapVest in 2024. The transaction has generated an attractive return, particularly given the short hold period2.
1 Following this transaction, ICGT will retain a small stake in Datasite through its commitment to ICG Strategic Equity V. At 31 January 2025 this indirect exposure represented 0.3% of the Portfolio value.
2 Does not necessarily reflect the expected future performance and should not be used to compare returns among multiple private equity funds.
Enquiries
| Analyst / Investor enquiries: | |
| Martin Li, Shareholder Relations, ICG | +44 (0) 20 3545 1816 |
| Nathan Brown, Deutsche Numis | +44 (0) 20 7260 1426 |
| David Harris, Cadarn Capital | +44 (0) 20 7019 9042 |
| Media: | |
| Clare Glynn, Corporate Communications, ICG | +44 (0) 20 3545 1395 |
| Website: | |
| www.icg-enterprise.co.uk |
About ICG Enterprise Trust
ICG Enterprise Trust is a leading listed private equity investor focused on creating long-term compounding growth by delivering consistently strong returns through selectively investing in profitable, cash-generative private companies, primarily in Europe and the US.
We invest in companies directly as well as through funds managed by ICG and other leading managers who focus on creating long-term value and building sustainable growth through active management and strategic change.
We have a long track record of delivering strong returns through a flexible mandate and highly selective approach that strikes the right balance between concentration and diversification, risk and reward.
Disclaimer
This report may contain forward looking statements. These written materials are not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration under the US Securities Act of 1933, as amended, or an exemption therefrom. The issuer has not and does not intend to register any securities under the US Securities Act of 1933, as amended, and does not intend to offer any securities to the public in the United States. No money, securities or other consideration from any person inside the United States is being solicited and, if sent in response to the information contained in these written materials, will not be accepted.
Latest directors dealings
- 53 seconds ago QinetiQ Group
- 22 minutes ago JPMorgan Emerging Markets Growth & Income plc
- 24 minutes ago National Grid
- 1 hour ago City of London Investment Group
- 1 hour ago BioPharma Credit